MUC1-targeting vaccines are currently in various stages of clinical trials, including: TG4010 (its safety and activity have been evaluated in phase II studies in several types of solid tumours) [141], Tecemotide (currently undergoing phase III clinical trials for non-small cell lung cancer) [142] and PANVAC (currently undergoing phase II clinical trials against colon and breast cancer) [143]. This evidence concerns the gene MUC1 and breast carcinoma.